Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001165 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 999
- Enrollment target
NCT00001165 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 999 participants.
The verdict
NCT00001165, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 999 participants
- Enrollment target
Study Summary
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors. Prior to the use of drugs to cure the ulcers, patients typically died due to severe ulcers. Because of such effective drugs to treat the ulcers it is more common to see patients dying due to the pancreatic tumors. The study will observe patients suffering from Zollinger-Ellison Syndrome and non-beta islet cell tumors and determine the effectiveness of combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin.
Interventions
- DRUG combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 1978-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001165
The ClinicalTrials.gov registry entry for NCT00001165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 999 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin is the first listed.
NCT00001165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001165 about?
NCT00001165 is a clinical study titled "Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas". Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors. Prior to the use of drugs to cure the ulcers, patients typically died due to severe ulcers. Bec...
What is the current status of trial NCT00001165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 999 participants. The study started on 1978-09. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00001165?
The interventions under investigation include: combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00001165?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.